Nanette Pettry
Nurse Practitioner · El Paso, TXNPI 1326062845
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,248 of the $15,820 with a category attached, or 64.8%. It is spread thinly across 25 manufacturers, the largest accounting for just 19.7%. Reporting peaked in 2024 at $6,622 and has fallen 58.7% since, to $2,735 in 2025. Among nurse practitioner clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 510 payments — averaging $31.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Phathom Pharmaceuticals, Inc.$3K
- Madrigal Pharmaceuticals$3K
- AbbVie$2K
- Johnson & Johnson$1K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$981
- plus $4K from 19 others
What the payments were for
- Consulting fees$1,2238%
- Speaking & faculty fees$4,11826%
- Food & beverage$10,24865%
- Education$2321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Phathom Pharmaceuticals, Inc. | 13 | $3,117 |
| Madrigal Pharmaceuticals | 14 | $3,084 |
| AbbVie | 110 | $2,292 |
| Johnson & Johnson(2 entities) | 76 | $1,421 |
| Takeda Pharmaceuticals U.S.A., Inc. | 46 | $1,028 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 69 | $981 |
| Ardelyx, Inc. | 21 | $733 |
| Pfizer | 27 | $659 |
| Bristol Myers Squibb | 31 | $401 |
| Aimmune Therapeutics, Inc. | 15 | $278 |
| Nestle Healthcare Nutrition Inc. | 17 | $254 |
| Intercept Pharmaceuticals, Inc. | 14 | $233 |
| Gilead | 9 | $224 |
| Daiichi Sankyo Inc. | 15 | $216 |
| Enterra Medical, Inc. | 1 | $160 |
| E.r. Squibb & Sons, L.L.C. | 4 | $154 |
| Merck | 9 | $128 |
| Novo Nordisk | 1 | $119 |
| Ferring Pharmaceuticals Inc. | 5 | $88 |
| Amgen | 3 | $72 |
| Redhill Biopharma Inc. | 3 | $52 |
| Lilly USA, LLC | 2 | $39 |
| Shield Therapeutics Inc | 2 | $33 |
| Alnylam Pharmaceuticals Inc. | 2 | $28 |
| Sandoz | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,820 in reported general payments places this provider in the 95th percentile of 5,422 nurse practitioner providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 112 | $388,155 |
| EntyvioVedolizumab | 13 | $128,921 |
| ZenpepLipase/Protease/Amylase | 43 | $106,306 |
| LinzessLinaclotide | 90 | $98,395 |
| CreonLipase/Protease/Amylase | 34 | $76,422 |
| Mesalamine | 51 | $9,841 |
| Famotidine | 397 | $7,927 |
| Ursodiol | 23 | $6,150 |
| Omeprazole | 299 | $5,569 |
| Colestipol Hcl | 37 | $4,164 |
| Mesalamine ErMesalamine | 14 | $3,810 |
| Balsalazide Disodium | 16 | $3,522 |
| Esomeprazole Magnesium | 53 | $3,076 |
| Sucralfate | 72 | $2,647 |
| Lactulose | 73 | $2,236 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Plenvu | $981 | $390,286127 claims |
| AbbVieLinzess, Creon | $2,292 | $174,817124 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Entyvio | $1,028 | $128,92113 claims |
| Aimmune Therapeutics, Inc.Zenpep | $278 | $106,30643 claims |
| SandozLansoprazole | $24 | $56727 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,422 nurse practitioner providers in Texas.
Other nurse practitioner in El Paso
- Amanda FrenchEl Paso$61K
- Lisa SelbyEl Paso$19K
- Miguel RodriguezEl Paso$17K
- Cecilia DavisAustin$262K
- Melanie MorrisHouston$254K
- Stephanie BrownHarlingen$235K
- Brittney MisercolaKilleen$223K
- Roger ChapmanTyler$211K
- Corrie BerkSan Antonio$155K
- Samantha OnealDallas$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.